All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death or transfer to ICUdetailed results RECOVERY, 2020 1.09 [0.99; 1.20]
1.09 [0.99 ; 1.20 ] RECOVERY, 2020 1 0% 4,836 NA not evaluable deathsdetailed results Cao, 2020 0.71 [0.36; 1.40]
Hung et al., 2020 0.47 [0.01; 24.30]
Nojomi, 2020 0.49 [0.04; 5.58]
Nojomi, 2020 2.04 [0.18; 23.27]
RECOVERY, 2020 1.03 [0.91; 1.17]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
Solaymani-Dodaran, 2021 1.22 [0.66; 2.26]
SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26]
0.99 [0.89 ; 1.09 ] Cao, 2020, Hung et al., 2020, Nojomi, 2020, Nojomi, 2020, RECOVERY, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, Solaymani-Dodaran, 2021, SOLIDARITY (lopi/rito), 2020 8 0% 9,355 moderate not evaluable deaths (time to event analysis only)detailed results REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
0.83 [0.65 ; 1.06 ] REMAP-CAP (lopinavir/ritonavir only), 2020 1 0% 645 NA not evaluable clinical deteriorationdetailed results ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
3.69 [0.37 ; 36.57 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 28 NA not evaluable clinical improvementdetailed results Cao, 2020 1.31 [0.94; 1.83]
Huang, 2020 1.37 [0.73; 2.56]
Hung et al., 2020 3.92 [1.66; 9.24]
1.72 [0.98 ; 3.01 ] Cao, 2020, Huang, 2020, Hung et al., 2020 3 64% 149 moderate not evaluable clinical improvement (14-day)detailed results Cao, 2020 1.94 [1.09; 3.48]
Huang, 2020 1.37 [0.73; 2.56]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
1.25 [0.73 ; 2.13 ] Cao, 2020, Huang, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020 3 72% 866 moderate not evaluable clinical improvement (28-day)detailed results Cao, 2020 1.59 [0.84; 3.03]
1.59 [0.84 ; 3.03 ] Cao, 2020 1 0% 199 NA not evaluable clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
3.16 [0.62 ; 16.06 ] Cao, 2020 1 0% 199 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.31 [0.94; 1.83]
Hung et al., 2020 3.92 [1.66; 9.24]
Solaymani-Dodaran, 2021 0.94 [0.75; 1.17]
1.43 [0.84 ; 2.45 ] Cao, 2020, Hung et al., 2020, Solaymani-Dodaran, 2021 3 82% 507 moderate not evaluable hospital dischargedetailed results Huang, 2020 2.00 [1.15; 3.47]
RECOVERY, 2020 0.98 [0.91; 1.05]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
1.02 [0.79 ; 1.32 ] Huang, 2020, RECOVERY, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020 3 79% 5,707 moderate not evaluable mechanical ventilationdetailed results Solaymani-Dodaran, 2021 1.62 [0.85; 3.08]
1.62 [0.85 ; 3.08 ] Solaymani-Dodaran, 2021 1 0% 373 NA not evaluable radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
Huang, 2020 1.33 [0.94; 1.88]
1.31 [0.93 ; 1.85 ] ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 2 0% 47 moderate not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
Huang, 2020 2.40 [0.26; 22.51]
0.58 [0.03 ; 12.80 ] ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 2 63% 47 moderate not evaluable viral clearance detailed results ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
Huang, 2020 1.20 [0.78; 1.85]
Hung et al., 2020 4.37 [1.86; 10.25]
1.95 [0.73 ; 5.23 ] ELACOI (lopinavir/ritonavir), 2020, Huang, 2020, Hung et al., 2020 3 72% 177 moderate not evaluable viral clearance (time to event analysis only)detailed results Hung et al., 2020 4.37 [1.86; 10.25]
4.37 [1.86 ; 10.25 ] Hung et al., 2020 1 0% 127 NA not evaluable viral clearance by day 14detailed results ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38]
Huang, 2020 1.09 [0.95; 1.26]
1.10 [0.95 ; 1.26 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Lopinavir/ritonavir), 2020, Huang, 2020 3 0% 119 moderate not evaluable viral clearance by day 7detailed results ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
Huang, 2020 1.20 [0.60; 2.40]
1.03 [0.60 ; 1.78 ] ELACOI (Lopinavir/ritonavir), 2020, ELACOI (lopinavir/ritonavir), 2020, Huang, 2020 3 0% 119 moderate not evaluable ICU admissiondetailed results Solaymani-Dodaran, 2021 1.23 [0.70; 2.18]
1.23 [0.70 ; 2.18 ] Solaymani-Dodaran, 2021 1 0% 373 NA not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27]
0.30 [0.07 ; 1.27 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
Hung et al., 2020 0.23 [0.01; 7.12]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
0.80 [0.31 ; 2.07 ] Cao, 2020, Hung et al., 2020, REMAP-CAP (lopinavir/ritonavir only), 2020 3 58% 938 moderate not evaluable adverse eventsdetailed results Huang, 2020 1.80 [0.14; 23.37]
1.80 [0.14 ; 23.37 ] Huang, 2020 1 0% 22 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-10 13:29 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
